Drugs and steatohepatitis

Seminars in Liver Disease

Volumn 22, Issue 2, 2002, Pages 185-194

  Farrell, Geoffrey C ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Amiodarone; Calcium channel blockers; Corticosteroids; Drugs; Estrogens; Hepatic fibrosis; Industrial hepatotoxicity; Insulin resistance syndrome; Methotrexate; Nonalcoholic steatohepatitis; Perhexiline maleate; Tamoxifen

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMANTADINE; AMIODARONE; AMITRIPTYLINE; AZACOSTEROL; CARBAMAZEPINE; CHLORCYCLIZINE; CHLOROQUINE; CHLORPHENTERMINE; CHLORPROMAZINE; CORTICOSTEROID; COTRIMOXAZOLE; CYTOCHROME P450 2D6; DILTIAZEM; ESTROGEN DERIVATIVE; FENFLURAMINE; HEXESTROL BIS(2 DIETHYLAMINOETHYL) ETHER; IMIPRAMINE; METHOTREXATE; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; PERHEXILINE MALEATE; PROPRANOLOL; REACTIVE OXYGEN METABOLITE; TAMOXIFEN; THIORIDAZINE; TRIPARANOL; TRIPELENNAMINE; UNINDEXED DRUG; VERAPAMIL;

CLINICAL FEATURE; DISEASE EXACERBATION; DNA POLYMORPHISM; DRUG ACCUMULATION; DRUG INDUCED DISEASE; DRUG OXIDATION; FATTY ACID OXIDATION; FATTY LIVER; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIVER FIBROSIS; LIVER MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW;

ADENOSINE TRIPHOSPHATE; ADRENAL CORTEX HORMONES; ANTINEOPLASTIC AGENTS, HORMONAL; CYTOCHROME P-450 CYP2D6; ESTROGENS; FATTY ACIDS; FATTY LIVER; HEPATITIS, TOXIC; HUMANS; INSULIN RESISTANCE; MITOCHONDRIA; OXIDATION-REDUCTION; POLYMORPHISM, GENETIC; REACTIVE OXYGEN SPECIES; TAMOXIFEN;

EID: 0036247430     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-30106     Document Type: Review

References (95)

1. Review: Nonalcoholic steatohepatitis
2. Fatty liver hepatitis and cirrhosis in obese patients
3. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
4. Liver fibrosis in overweight patients
5. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity
6. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying liver disease
7. Liver pathology and the metabolic syndrome X in severe obesity
8. Nonalcoholic steatohepatitis: Definition and pathology
9. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions
10. Drug-induced liver disease
11. Hepatotoxicity
12. Drugs and non-alcoholic steatohepatitis
13. Association of nonalcoholic fatty liver disease with insulin resistance
14. NASH and insulin resistance: Insulin hypersecretion, and specific association with the insulin resistance syndrome
15. Etiopathogenesis of nonalcoholic steatohepatitis
16. Non-alcoholic fatty liver: Another feature of the metabolic syndrome?
17. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
18. Insulin resistance and mitochondrial abnormalities in NASH: A cool look into a burning issue
19. Clinico-pathological and electron microscopical studies on a coronary dilating agent: 4,4′-diethyl-aminoethoxyhexestrol-induced liver injuries
20. Perhexiline maleate-induced hepatitis
21. Perhexiline maleate-induced cirrhosis
22. Impaired oxidation of debrisoquine in patients with perhexiline liver injury
23. Amiodarone-induced hepatic phospholipidosis: Correlation of morphological and biochemical findings in an animal model
24. Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine
25. Alcoholic-like liver lesions induced by nifedipine
26. Tous les inhibiteurs calciques peuvent-ils entrainer des lésions d'hépatite alcoolique?
27. Tamoxifen-associated steatohepatitis - Report of three cases
28. Tamoxifen-induced steatohepatitis
29. Tamoxifen-induced steatohepatitis
30. Cirrhosis with steatohepatitis after adjuvant tamoxifen
31. Tamoxifen-induced fatty liver in patients with breast cancer
32. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients
33. Cirrhosis with nonalcoholic steatohepatitis: Role of tamoxifen
34. Liver damage associated with occupational exposure to organic solvents in house painters
35. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes
36. Hepatotoxicity due to mitochondrial dysfunction
37. Mitochondria in steatohepatitis
38. Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria
39. Non-alcoholic steatohepatitis: Impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis
40. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis
41. Cytochrome P450 and oxidative stress
42. Peroxisomal β-oxidation and steatohepatitis
43. Diabetic KKAγ mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones
44. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
45. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus
46. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
47. Mitochondrial toxicity and HIV therapy
48. Adverse reactions during treatment with amiodarone hydrochloride
49. Amiodarone: Clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias
50. Amiodarone for control of sustained ventricular tachyarrhythmia: Clinical and electrophysiologic effects in 51 patients
51. Amiodarone
52. Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients
53. Amiodarone hepatotoxicity simulating alcoholic liver disease
54. Histopathologic analysis of suspected amiodarone hepatotoxicity
55. Fatal amiodarone hepatotoxicity
56. The evolving spectrum of amiodarone hepatotoxicity
57. Fatal hepatotoxicity following oral administration of amiodarone
58. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: A case report and review of the literature
59. Images in hepatology. Iodine accumulation in the liver during long-term treatment with amiodarone
60. Optimal management of amiodarone therapy: Efficacy and side effects
61. Histopathology of drug-induced liver disease
62. Hepatocellular carcinoma after long-term tamoxifen therapy
63. Chemoprevention of breast cancer by tamoxifen: Risks and opportunities
64. Tamoxifen-induced submassive hepatic necrosis
65. Tamoxifen-induced nonalcoholic steatohepatitis and bezafibrate
66. Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer
67. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment
68. Nonalcoholic steatohepatitis induced by massive doses of synthetic estrogen
69. Nonalcoholic fatty liver with alcoholic hyaline after long-term glucocorticoid therapy
70. Verapamil-induced hepatotoxicity
71. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity
72. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: Lactic acidosis, risk factors and therapeutic options
73. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: Report of two patients and review of the literature
74. Hepatomegaly with severe steatosis in HIV-seropositive patients
75. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion
76. Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddI)
77. Fulminant hepatitis with severe lactic acidosis in HIV-infected patients on didanosine therapy
78. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy
79. Adverse effects of antiretroviral therapy
80. HIV-protease inhibitors
81. Acute hepatitis in HIV-infected patients during ritonavir treatment
82. Hepatotoxicity associated with ritonavir
83. Severe hepatitis in three AIDS patients treated with indinavir
84. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-worldwide, 1997-2000
85. Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases
86. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient
87. Severe lactic acidosis induced by nucleoside analogues in an HIV-infected man
88. Methotrexate and histologic hepatic abnormalities: A meta-analysis
89. The role of non-alcoholic steatohepatitis (NASH) in methotrexate-induced liver injury
90. Morphologic alterations in patients with alpha-methyldopa-induced liver damage after short- and long-term exposure
91. Non-alcoholic steatohepatitis induced by carbamazepine and variegate porphyria
92. Clinical and pathologic characteristics associated with occupational exposure to dimethylformamide
93. Nonalcoholic steatohepatitis: A toxic liver disease in industrial workers
94. Clinico-biochemical evolution and late hepatic lesions in the toxic oil syndrome